These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 32824865)

  • 21. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
    Wilkerson A; Kim J; Huang AY; Zhang M
    Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity, Inflammation, and Prostate Cancer.
    Fujita K; Hayashi T; Matsushita M; Uemura M; Nonomura N
    J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30736371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
    Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
    Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of inflammatory factors by double-stranded RNA receptors in breast cancer cells.
    Venkatesh A; Nandigam H; Muccioli M; Singh M; Loftus T; Lewis D; Pate M; Benencia F
    Immunobiology; 2018; 223(6-7):466-476. PubMed ID: 29331323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration.
    Liu Q; Tong D; Liu G; Gao J; Wang LA; Xu J; Yang X; Xie Q; Huang Y; Pang J; Wang L; He Y; Zhang D; Ma Q; Lan W; Jiang J
    Clin Cancer Res; 2018 Nov; 24(22):5622-5634. PubMed ID: 30012567
    [No Abstract]   [Full Text] [Related]  

  • 26. Tumor-associated myeloid cells as guiding forces of cancer cell stemness.
    Sica A; Porta C; Amadori A; Pastò A
    Cancer Immunol Immunother; 2017 Aug; 66(8):1025-1036. PubMed ID: 28401258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling.
    Hayashi T; Fujita K; Nojima S; Hayashi Y; Nakano K; Ishizuya Y; Wang C; Yamamoto Y; Kinouchi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Nagahara A; Ujike T; Uemura M; Pena MDCR; Gordetsky JB; Morii E; Tsujikawa K; Netto GJ; Nonomura N
    Clin Cancer Res; 2018 Sep; 24(17):4309-4318. PubMed ID: 29776955
    [No Abstract]   [Full Text] [Related]  

  • 28. Suppression of T cells by myeloid-derived suppressor cells in cancer.
    Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
    Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of toll-like receptor 4 in tumor microenvironment.
    Li J; Yang F; Wei F; Ren X
    Oncotarget; 2017 Sep; 8(39):66656-66667. PubMed ID: 29029545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.
    Davis RJ; Van Waes C; Allen CT
    Oral Oncol; 2016 Jul; 58():59-70. PubMed ID: 27215705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer.
    Pogoda K; Pyszniak M; Rybojad P; Tabarkiewicz J
    Oncol Lett; 2016 Dec; 12(6):4785-4794. PubMed ID: 28101225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy.
    Neophytou CM; Pierides C; Christodoulou MI; Costeas P; Kyriakou TC; Papageorgis P
    Front Oncol; 2020; 10():899. PubMed ID: 32656079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum amyloid A3 exacerbates cancer by enhancing the suppressive capacity of myeloid-derived suppressor cells via TLR2-dependent STAT3 activation.
    Lee JM; Kim EK; Seo H; Jeon I; Chae MJ; Park YJ; Song B; Kim YS; Kim YJ; Ko HJ; Kang CY
    Eur J Immunol; 2014 Jun; 44(6):1672-84. PubMed ID: 24659444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
    Hanna BS; Öztürk S; Seiffert M
    Mol Immunol; 2019 Jun; 110():77-87. PubMed ID: 29173971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Notch Signaling in Macrophages in the Context of Cancer Immunity.
    Palaga T; Wongchana W; Kueanjinda P
    Front Immunol; 2018; 9():652. PubMed ID: 29686671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion.
    Qiu Y; Chen T; Hu R; Zhu R; Li C; Ruan Y; Xie X; Li Y
    Biomark Res; 2021 Oct; 9(1):72. PubMed ID: 34625124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemopreventive Effects of Phytochemicals and Medicines on M1/M2 Polarized Macrophage Role in Inflammation-Related Diseases.
    Koh YC; Yang G; Lai CS; Weerawatanakorn M; Pan MH
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice.
    Hanazawa A; Ito R; Katano I; Kawai K; Goto M; Suemizu H; Kawakami Y; Ito M; Takahashi T
    Front Immunol; 2018; 9():152. PubMed ID: 29456539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune mediators in the tumor microenvironment of prostate cancer.
    Dai J; Lu Y; Roca H; Keller JM; Zhang J; McCauley LK; Keller ET
    Chin J Cancer; 2017 Mar; 36(1):29. PubMed ID: 28292326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer: MDSCs and immune system in Prostate cancer.
    Sanaei MJ; Salimzadeh L; Bagheri N
    J Leukoc Biol; 2020 Jan; 107(1):43-56. PubMed ID: 31721301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.